Regenerative Therapy and Immune Modulation Using Umbilical Cord Blood-Derived Cells
Regenerative Therapy and Immune Modulation Using Umbilical Cord Blood-Derived Cells
复制标题
DOI：
10.1016/j.bbmt.2015.05.022
复制
发表时间：
2015-09-01
影响因子：
4.3
通讯作者：
Allan, David S.
中科院分区：
文献类型：
--
作者：
Damien, Pauline;Allan, David S.
自1988年第一次脐带血移植以来，脐带血已成为造血移植细胞来源的重要选择。除了其在再生血液和免疫系统以治疗血液疾病和遗传代谢性疾病中的作用外，非杂型祖细胞在脐带血中的作用还导致了脐带血在再生治疗和免疫调节中的新兴和新兴使用。在这篇综述中，我们使用脐带血细胞（例如间充质基质细胞，内皮样祖细胞等）提供了有关临床和临床前研究的更新。我们还提供有关使用基因治疗和微囊泡相关策略将脐带血细胞用作治疗剂的车辆的洞察力。此外，脐带血可以为再生应用提供必不可少的试剂。使用脐带血细胞的临床活性正在迅速增加，这项综述旨在提供有关此快速发展领域中巨大潜力的重要更新。 （c）2015美国血液和骨髓移植学会。
Since the first cord blood transplantation in 1988, umbilical cord blood has become an important option as a source of cells for hematopoietic transplantation. Beyond its role in regenerating the blood and immune systems to treat blood diseases and inherited metabolic disorders, the role of nonhematopoietic progenitor cells in cord blood has led to new and emerging uses of umbilical cord blood in regenerative therapy and immune modulation. In this review, we provide an update on the clinical and preclinical studies using cord blood derived cells such as mesenchymal stromal cells, endothelial-like progenitor cells, and others. We also provide insight on the use of cord blood cells as vehicles for the delivery of therapeutic agents through gene therapy and microvesicle-associated strategies. Moreover, cord blood can provide essential reagents for regenerative applications. Clinical activity using cord blood cells is increasing rapidly and this review aims to provide an important update on the tremendous potential within this fast-moving field. (C) 2015 American Society for Blood and Marrow Transplantation.